Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
about
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.New Challenges in the Management of Diffuse Large B-Cell Lymphoma.Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.SLE and Non-Hodgkin's Lymphoma: A Case Series and Review of the LiteratureClinical implications of the molecular subtypes of diffuse large B-cell lymphoma.Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients
P2860
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@en
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@nl
type
label
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@en
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@nl
prefLabel
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@en
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@nl
P2093
P50
P356
P1433
P1476
Immunophenotype and intermedia ...... arge B-cell lymphoma patients.
@en
P2093
Alessandro Broccoli
Amalia De Renzo
Francesco Bacci
Stefano A Pileri
Vittorio Stefoni
P304
P356
10.1002/CNCR.25307
P407
P577
2010-08-24T00:00:00Z